Halozyme Therapeutics (NASDAQ:HALO – Get Free Report)‘s stock had its “market outperform” rating reaffirmed by JMP Securities in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $72.00 target price on the biopharmaceutical company’s stock. JMP Securities’ price target indicates a potential upside of 87.70% from the stock’s […]